Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

Core Insights - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology markets, including treatments for atopic dermatitis, asthma, and chronic obstructive pulmonary disease [1][3] - The company will present data from its ongoing Phase 1 clinical trial of APG777, an anti-IL-13 antibody, at the ACAAI 2024 Annual Scientific Meeting [1][2] Company Overview - Apogee Therapeutics aims to address limitations of existing therapies by utilizing advanced antibody engineering to optimize half-life and efficacy [3] - The company is initially developing APG777 for atopic dermatitis, which is identified as a large and under-penetrated market within the inflammatory and immunology sector [3] - Apogee has a portfolio with four validated targets and seeks to achieve best-in-class efficacy through both monotherapies and combinations of its novel antibodies [3]